A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With T2DM With Inadequate Glycemic Control on 1, 2 or 3 Oral Glucose-lowering Agents
Latest Information Update: 15 Feb 2023
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ORA-D-013-1
- Sponsors Oramed Pharmaceuticals
- 09 Feb 2023 According to Oramed media release, the company will conduct a comprehensive analysis of the data from this study.
- 02 Feb 2023 Status changed from active, no longer recruiting to discontinued because primary end-point was not met.
- 11 Jan 2023 Results published in an Oramed Pharmaceuticals media release.